<DOC>
	<DOCNO>NCT00113269</DOCNO>
	<brief_summary>The purpose study compare safety efficacy different induction agent ( alemtuzumab , basiliximab rabbit anti-thymocyte globulin ) renal transplant recipient treat tacrolimus , mycophenolate mofetil ( MMF ) rapid steroid withdrawal .</brief_summary>
	<brief_title>Safety/Efficacy Induction Agents With Tacrolimus , MMF , Rapid Steroid Withdrawal Renal Transplant Recipients</brief_title>
	<detailed_description>A 2 arm ( 1 Active , 1 Active Control ) study compare safety efficacy different induction agent ( alemtuzumab , basiliximab rabbit anti-thymocyte globulin ) renal transplant recipient treat tacrolimus , MMF rapid steroid withdrawal .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Recipient primary retransplanted deceased donor kidney primary retransplanted nonhuman leukocyte antigen ( HLA ) live donor kidney ( ie. , HLA identical 0 antigen mismatch decease donor kidney allow ) . Patient previously receive organ transplant kidney Patient receive chronic steroid therapy time transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Anti-rejection therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Therapy , antirejection</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Transplantation , Kidney</keyword>
	<keyword>Transplantation , Renal</keyword>
	<keyword>Grafting , Kidney</keyword>
</DOC>